

# Development of Novel *In Vitro* Assay Technologies for Human Thyroid Screening


Chad Deisenroth, Ph.D.  
Center for Computational Toxicology and Exposure  
Contact: [deisenroth.chad@epa.gov](mailto:deisenroth.chad@epa.gov)  
March 14<sup>th</sup>, 2021

*The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the U.S. EPA. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.*

## Outline

- Current Methods for Evaluating Thyroid Toxicity
- Challenges with In Vitro Thyroid Testing: Predicting Thyroid Hormone Disruption from High-throughput Assays
- Development of a Human Thyroid Organotypic Culture Model Assay
- Development of Novel Immortalized Human Thyrocyte Cell Lines

## Endocrine Toxicology: Why Do We Care About Thyroid?



- Thyroid hormones are essential for normal growth, development, cell differentiation, and energy homeostasis.
- Thyroid dysfunction is characterized by under- (hypothyroidism) or over- (hyperthyroidism) activity of the gland.
- Thyroid dysfunction has an impact on four major adverse health outcomes:
  - Neurodevelopment and function
  - Cancer
  - Cardiovascular disease
  - Lipid metabolism
- Environmental chemical exposures associated with thyroid dysfunction:
  - Perchlorate and thiocyanate (with iodine deficiency)
  - Mercury and arsenic
  - Certain organochlorine pesticides, poly-aromatic hydrocarbons, and perfluorinated compounds

# Thyroid Testing in the Endocrine Disruptor Screening Program

| Endocrine Pathway | Tier 1 Screening Battery |                                 |            |                      |                  |               |              |               |                 |                          | Tier 2 Testing Assays         |                             |                                     |                                 |                                      |
|-------------------|--------------------------|---------------------------------|------------|----------------------|------------------|---------------|--------------|---------------|-----------------|--------------------------|-------------------------------|-----------------------------|-------------------------------------|---------------------------------|--------------------------------------|
|                   | ER Binding               | ERα Transcriptional Activation* | AR Binding | Aromatase Inhibition | Steroidogenesis* | Uterotrophic* | Hershberger* | Pubertal Male | Pubertal Female | Amphibian Metamorphosis* | Fish Short Term Reproduction* | Rat 2-gen/Extended One-Gen* | Medaka Extended One-Gen Repro Test* | Amphibian Growth and Dev Assay* | Japanese Quail Two Gen Toxicity Test |
| E+                | ■                        | ■                               |            |                      | ■                | ■             |              |               | ■               |                          | ■                             | ■                           | ■                                   | ■                               | ■                                    |
| E-                | ■                        |                                 |            | ■                    | ■                |               |              |               | ■               |                          | ■                             | ■                           | ■                                   | ■                               | ■                                    |
| A+                |                          |                                 | ■          |                      | ■                |               | ■            | ■             |                 |                          | ■                             | ■                           | ■                                   | ■                               | ■                                    |
| A-                |                          |                                 | ■          |                      | ■                |               | ■            | ■             |                 |                          | ■                             | ■                           | ■                                   | ■                               | ■                                    |
| HPT Axis          |                          |                                 |            |                      |                  |               |              | ■             | ■               | ■                        |                               | ■                           |                                     | ■                               | ■                                    |

The current EDSP assay battery evaluates effects of chemical exposures on estrogen, androgen, and thyroid endocrine pathways


- No *in vitro* tests for thyroid endpoints
- No human representation for thyroid
- Too reliant on animal tests

## ***In vivo* endpoints for thyroid-related endocrine testing in guideline studies**

- Serum T3, T4, and TSH
- Thyroid and Pituitary weights
- Thyroid Histopathology

| Screening Assay                        | Thyroid weight | Pituitary weight | Thyroid Histopathology | Serum TH levels         |
|--|----------------|------------------|------------------------|-------------------------|
| OECD TG 407                            | +              | +                | +                      | + (optional)            |
| OECD TG 408                            | -              | -                | +                      | -                       |
| OECD TG 416                            | +              | +                | -                      | -                       |
| OECD TG 422                            | -              | -                | +                      | -                       |
| OECD TG 441                            | -              | -                | -                      | + (T3 and T4, optional) |
| OECD TG 443                            | +              | +                | + (optional)           | + (T4 and TSH)          |
| OECD TG 451                            |                |                  | +                      |                         |
| OECD TG 452                            | +              |                  | +                      |                         |
| OECD TG 453                            | +              |                  | +                      |                         |
| EPA 15-day intact adult male rat assay | +              | -                | +                      | +                       |
| EPA Pubertal male                      | +              | +                | +                      | + (T4 and TSH)          |
| EPA Pubertal female                    | +              | +                | +                      | + (T4 and TSH)          |

## Mapping Mechanism-based Testing Strategies for Thyroid Hormone Homeostasis




**Murk, A. J. et al.** Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. *Toxicology in vitro*. (2013).

**OECD** New Scoping Document on in vitro and ex vivo Assays for the Identification of Modulators of Thyroid Hormone Signalling. (2014).

**EPA** Continuing development of alternative high-throughput screens to determine endocrine disruption, focusing on androgen receptor, steroidogenesis, and thyroid pathways. *FIFRA SAP*, November 28-30. (2017).

# In Vitro/In Vivo Thyroid Screening: Proposed Thyroid Adverse Outcome Pathway (AOP) Network for Chemical Screening and Assessment



## Thyroid AOP network architecture

- Framework to organize and evaluate thyroid data
- Identify data gaps
- Examine causality between key events


What are the quantitative relationships between MIEs and Key Events that drive adverse outcomes?

What additional bioassay data can be generated to reduce existing data uncertainty and support predictive modeling of thyroid disrupting chemicals?


What *in vitro* assay technologies are needed to address key events in the thyroid AOP framework?



## Challenges with *In Vitro* Thyroid Testing: Predicting Thyroid Hormone Disruption from High-throughput Assays




- The uncertainty surrounding the specificity of active chemicals identified in thyroid gland-related screens and the relevance to phenotypic effects on *in vivo* human thyroid hormone synthesis are notable data gaps for hazard identification of thyroid disrupting chemicals (TDCs).
- Additional data linking MIE effects to thyroid hormone synthesis and secretion could support predictive modeling of TDCs for related adverse outcomes.



| Target Gene | Assay                | Environmental Chemicals Screened | Active Chemicals | Reference  |
|-------------|----------------------|----------------------------------|------------------|--|
| TSHR        | Engineered Cell Line | 7871                             | 825              | TCPL: TOX21_TSHR_Agonist, TOX21_TSHR_Antagonist              |
| TPO         | Microsomal Enzyme    | 1074                             | 314              | K. Paul Friedman et al, ToxSci, 151(1), 2016, 160-180        |
| NIS         | Engineered Cell Line | 293                              | 137              | J. Wang et al, EnvironSciTechn, 52, 2018, 5417-5426          |
| NIS         | Engineered Cell Line | 768                              | 172              | J. Wang et al, Environment International, 126, 2019, 377-386 |
| DIO 1       | Recombinant Enzyme   | 292                              | 50               | M. Horning et al, ToxSci, 162(2), 2018, 570-581              |
| DIO 1       | Recombinant Enzyme   | 1819                             | 221              | J. Olker et al, ToxSci, 168(2), 2019, 430-442                |
| DIO 2       | Recombinant Enzyme   | 1819                             | 303              | J. Olker et al, ToxSci, 168(2), 2019, 430-442                |
| IYD         | Recombinant Enzyme   | 293                              | 28               | J. Olker et al, 2019, 58 <sup>th</sup> SOT Annual Meeting    |

## Challenges with *In Vitro* Thyroid Testing: Cell Type and Architecture are Critical Determinants for Hormone Synthesis



### Cell Type

- No primary or thyroid cell lines, of any species, demonstrate appreciable capacity for thyroid hormone synthesis in 2D models
- Primary thyrocytes lose essential functions when cultured in conventional monolayer systems

### Cell Architecture

- Structure-function relationship: Follicular morphology is a critical feature for retaining hormone synthesis dynamics





**SOT** | Society of  
Toxicology  
academic.oup.com/toxsci

TOXICOLOGICAL SCIENCES, 174(1), 2020, 63–78


doi: 10.1093/toxsci/kfz238

Advance Access Publication Date: December 6, 2019

Research Article


## Development of an In Vitro Human Thyroid Microtissue Model for Chemical Screening

Chad Deisenroth <sup>\*,1</sup>, Valerie Y. Soldatow, <sup>†</sup> Jermaine Ford, <sup>‡</sup> Wendy Stewart, <sup>\*</sup> Cassandra Brinkman, <sup>\*</sup> Edward L. LeCluyse, <sup>†</sup> Denise K. MacMillan, <sup>‡</sup> and Russell S. Thomas <sup>\*</sup>



**Study objective:** Develop a medium-throughput organotypic screening assay comprised of reconstructed human thyroid microtissues to quantitatively evaluate the disruptive effects of chemicals on thyroid hormone synthesis and secretion.

# Experimental Design: Characterization of 2D vs 3D Culture Formats



| Culture Model Design Specifications |  |
|-------------------------------------|--|
| Donors                              | Multiple (Tissue and Cells)                    |
| Cells                               | Human Primary Thyrocytes                       |
| Culture Format                      | 2D vs 3D                                       |
| Extracellular Matrix                | 2D (None)                                      |
|                                     | 3D (Matrigel)                                  |
| Plate Format                        | 96 well  |
| Culture Medium                      | Humanized 7 homeostatic additives (h7H) medium |
| Serum                               | FBS (Day 0-8)                                  |
|                                     | CS-FBS (Day 8-20)                              |
| TSH Exposures                       | 0, 1, 5 mU/ml                                  |
| Incubation Period                   | 0-20 Days                                      |

# Thyroid Procurement: LifeNet Health Institute of Regenerative Medicine

- Institute of Regenerative Medicine develops innovative or novel uses of donor tissues and organs through sound scientific and clinical research
- **Thyroid:** Procurement, digestion, expansion, cryopreservation



| Donor | LNH ID  | Age | Gender | Race             | BMI |
|-------|---------|-----|--------|------------------|-----|
| 1     | 1721880 | 32  | M      | Caucasian        | 22  |
| 2     | 1722161 | 21  | M      | Caucasian        | 32  |
| 3     | 1811621 | 66  | M      | African American | 35  |
| 4     | 1817005 | 27  | M      | Caucasian        | 19  |
| 5     | 1818646 | 31  | M      | Caucasian        | 31  |
| 6     | 1910289 | 18  | M      | Caucasian        | 22  |
| 7     | 1910552 | 36  | M      | Caucasian        | 37  |
| 8     | 1910594 | 17  | M      | African American | 27  |


**Table 1. Donor Specifications.** LifeNet Health donor identification number (LNH ID) for all eight euthyroid donors examined in this study. Specifications for age, gender, race, and body mass index (BMI) are noted.

**Mean Age:** 31 [Range:17-66] years  
**Gender:** Male  
**Race:** Caucasian and African American  
**Mean Body Mass Index:** 28 [Range: 19-37]


# Donor Thyrocyte Characterization: Enrichment of Follicular Epithelial Cells




NKX2-1



Cytokeratin 7



Thyroglobulin




| Biomarker | IgG   |      |   | IgG, kappa |      |   | NKX2-1 |      |   | KRT7  |      |   | TG    |       |   |
|-----------|-------|------|---|------------|------|---|--------|------|---|-------|------|---|-------|-------|---|
|           | % POS | SEM  | N | % POS      | SEM  | N | % POS  | SEM  | N | % POS | SEM  | N | % POS | SEM   | N |
| NKX2-1    | 1.91  | 0.50 | 6 | -          | -    | - | 95.18  | 1.74 | 6 | -     | -    | - | -     | -     | - |
| KRT7      | -     | -    | - | 0.30       | 0.14 | 6 | -      | -    | - | 90.52 | 2.47 | 6 | -     | -     | - |
| TG        | -     | -    | - | 1.93       | 1.31 | 6 | -      | -    | - | -     | -    | - | 53.37 | 16.10 | 6 |

Donors LNH 1722161, 1817005, 1818646, 1910289, 1910552, 1910594


**Table 3. Biomarker Image Cytometry.** The cell-level frequency of IgG isotype controls ( $\alpha$ -Mouse IgG kappa and  $\alpha$ -Rat IgG), NK2 Homeobox 1 (NKX2-1), Keratin 7 (KRT7), and Thyroglobulin (TG) staining were quantitatively evaluated by high-content imaging across 6 independent human donors for verification of thyroid follicular epithelial cell enrichment. Data are the summary statistics presented as mean % positive (% Pos)  $\pm$  SEM (n=6).

# Donor Thyrocyte Characterization: 2D vs 3D Morphology





## Donor Thyrocyte Characterization: Follicle-like Architecture












**Donor LNH1722161:** Confocal series of 3D microtissue.



## Gene Expression Analysis: 2D vs 3D vs Tissue




| Gene                     | Species |
|--------------------------|---------|
| <i>TSHR</i>              | Human   |
| <i>TG</i>                | Human   |
| <i>TPO</i>               | Human   |
| <i>SLC5A5 (NIS)</i>      | Human   |
| <i>SLC26A4 (Pendrin)</i> | Human   |
| <i>PAX8</i>              | Human   |
| <i>NKX2-1</i>            | Human   |
| <i>FOXE1</i>             | Human   |
| <i>DUOX1</i>             | Human   |
| <i>DUOX2</i>             | Human   |
| <i>DUOXA1</i>            | Human   |
| <i>DUOXA2</i>            | Human   |
| <i>TBP</i>               | Human   |



- Increased differentiation in a 3D model format
- Model- and TSH-dependent increase in genes regulating thyroid hormone synthesis


## TSH-induced Thyroglobulin Production




Donor LNH1817005 (n=4)

- Thyroglobulin production increases in a dose- and time-dependent manner
- TSH-dependent induction supports functional TSH receptor (TSHR) activity







# Thyroid Hormone Synthesis and Secretion




- Data support iodide organification and T<sub>4</sub>/T<sub>3</sub> synthesis exclusively in a 3D model



## Thyroid Disrupting Reference Chemicals


| Name                  | Structure  | CASRN        | Target | Classification   |
|-----------------------|--|--------------|--------|------------------|
| Dimethyl Sulfoxide    |   | 67-68-5      | -      | Solvent Control  |
| Methimazole           |   | 60-56-0      | TPO    | TPO Inhibitor    |
| 6-Propyl-2-thiouracil |   | 51-52-5      | TPO    | TPO Inhibitor    |
| Sodium Perchlorate    |   | 7601-89-0    | NIS    | NIS Inhibitor    |
| VA-K-14 HCl           |  | 1171341-19-7 | TSHR   | TSHR Antagonist  |
| Benzophenone 3        |  | 131-57-7     | -      | Negative Control |

# Evaluation of Reference Chemical Inhibition of Thyroid Hormone Synthesis in a 3D Microtissue Culture Model





| Chemical              | IC <sub>50</sub> (μM) | E <sub>max</sub> (% T4) | LEC (μM) |
|-----------------------|-----------------------|-------------------------|----------|
| Methimazole           | 0.129                 | 53.0                    | 1        |
| 6-Propyl-2-thiouracil | 0.172                 | 49.3                    | 1        |
| Sodium Perchlorate    | 3.23                  | 60.5                    | 10       |
| VA-K-14 HCl           | 5.61                  | 72.3                    | 10       |
| Benzophenone 3        | -                     | -                       | -        |

## Summary: 3D Human Thyroid Model



- **Impact:** An *in vitro* model of the human thyroid that is fully competent in thyroid hormone synthesis
- **Phenotypic Relevance:** Follicular-like morphology, TSHR activation, thyroglobulin synthesis, iodide uptake, thyroid hormone synthesis and secretion
- **Screening Throughput:** Amenable to medium-throughput (10s-100s), concentration-response testing of HTS prioritized hits
- **Automation Accessible:** Automated liquid handling, acoustic dosing, and high-content imaging
- **Sampling Design:** Cell culture supernatant sampling (Thyroid Hormone and Thyroglobulin) enables kinetic testing and chronic-dosing paradigms
- **Applications:** Drug and chemical testing, organ-on-chip technologies, thyroid disease research and modeling






## Expanding Assay Transfer and Reproducibility: Identification of Human Thyrocyte Cell Lines


**Question:** Is there an alternative cell type to recapitulate thyroid hormone synthesis in the 3D microtissue assay?

**Options:**

1. Primary thyrocytes
2. Immortalized thyrocyte cell line
3. Stem cell-derived thyrocytes
4. Thyroid tumor-derived cell line



## Thyrocyte Cell Lines May Not Retain Key Functional Features of Primary Thyrocytes




**Cell Line:** Fischer Rat Thyrocyte Line (FRTL-5) most commonly used in thyroid-related studies. (est 1980)

**Evaluation:** Medium formulations for rat (6H5) and human (h7H) in 3D culture model.  $\pm$ TSH (0-10 mU/ml).


**Results:** Self-organized morphology consistent with primary human thyrocytes, but Thyroglobulin production (TG) and Thyroid Hormone synthesis (T4) not detected.

**Conclusion:** Immortalized cell lines age! Loss of phenotypic stability is a common observation for thyroid-derived epithelial cells. Genetic drift and adaptation to cell culture conditions over many population doublings can result in physiological deviation from the tissue of origin.



### CI-SCREEN



generation of expandable and functional cells<sup>1</sup>



**Objective:** Create a novel early passage immortalized human thyrocyte line that retains functions of primary thyrocytes.



## InSCREENeX CI-SCREEN Technology

- The CI-SCREEN technology builds upon a unique optimized gene library of 33 genes associated with apoptosis, cell cycle control and stemness.
- After transduction with the library, all generated cell lines are screened for self-selected clonal isolates with expansion capacity consistent with immortalization.



- The CI-SCREEN technology identifies cell type-specific expansion cocktails.
- Screening a high number of immortalized cell lines identifies immortalization gene sets that are cell type specific.






### Evaluation


- Thyroid biomarker expression
- Karyotype
- Proliferation rates
- Morphology in 2D and 3D culture formats
- TSH Receptor function
- Thyroglobulin expression
- Thyroid hormone synthesis

### Findings

- Novel immortalized human thyrocyte cell lines retain many key morphological and functional features of primary thyrocytes suitable for select phenotypes.



|   | Thy 1 (A5-1) |          | Thy 2 (A1) |          | Thy 3 (AA-1) |          | Thy 4 (AA-2) |          |
|---|--------------|----------|------------|----------|--------------|----------|--------------|----------|
| Biomarker   | h7H          | huThyrec | h7H        | huThyrec | h7H          | huThyrec | h7H          | huThyrec |
| NKX2-1  | 96.5         | 96.7     | 98.5       | 98.5     | 93.9         | 92.3     | 99.1         | 98.8     |
| KRT7  | 74.9         | 91.7     | 79         | 93.2     | 72           | 89.2     | 61.8         | 81.7     |
| TG  | 4.3          | 1.8      | 0.5        | 1.9      | 2.3          | 0.6      | 2.9          | 0.6      |
| Mean expression frequency [% Pos] of 3 technical replicates |              |          |            |          |              |          |              |          |



## Acknowledgements



Denise MacMillan  
Jermaine Ford  
Wendy Stewart  
Cassandra Brinkman  
Kristen Hopperstad  
Andrew Eicher  
Russell Thomas  
Katie Paul-Friedman  
Grace Patlewicz  
Ann Richard  
Mahmoud Shobair  
Mark Nelms  
Dan Hallinger  
Susan Laws  
Tammy Stoker  
Jun Wang  
Angela Buckalew



Valerie Soldatow  
Ed LeCluyse  
Jeff Thomas  
Gary Walters  
Tino Balbuena  
Kristina Wolf  
Jingsong Chen  
Rony Thomas



Tobias May  
Tom Wahlicht  
Theresa Truschel  
Sophia David  
Georg Wolf



US Environmental Protection Agency  
Research Triangle Park, North Carolina